🏥
🏥 Health
Ozempic and Wegovy Work — But Covering Millions of Patients Could Bankrupt Insurers
GLP-1 drugs like Ozempic, Wegovy, and Zepbound deliver strong health outcomes, but covering them for all eligible patients could overwhelm insurance budgets by billions of dollars. Researchers call for better long-term clinical support to sustain the drugs' benefits and warn that cheaper compounded versions circulating on the market may pose serious safety risks. The funding gap is described as a systemic challenge requiring structural solutions.
Comments
No comments yet
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!